Jeroen J. Bueren-Van

Utrecht, UT 3584CT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications.

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications.

Journal: Cancers

Published: March 18, 2025

Systematic study of tissue factor expression in solid tumors.

Systematic study of tissue factor expression in solid tumors.

Journal: Cancer reports (Hoboken, N.J.)

Published: January 07, 2022

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Journal: Cancer discovery

Published: September 21, 2021

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.

Journal: Nature cancer

Published: August 10, 2020

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Journal: Immunological reviews

Published: February 12, 2016

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Journal: Haematologica

Published: October 06, 2015

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: June 15, 2015

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.

Journal: mAbs

Published: March 12, 2015

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.

Journal: Haematologica

Published: December 17, 2014

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.

Journal: Transfusion

Published: August 09, 2014

Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.

Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 21, 2012

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Journal: Neoplasia (New York, N.Y.)

Published: November 23, 2011

Showing 1-12 of 12

Last Updated: 09/26/2026